INOVIO PHARMACEUTICALS, INC. Net Change in Cash
INOVIO PHARMACEUTICALS, INC. (INO) reported Net Change in Cash of -$12.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$18.00M.
- INOVIO PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$25.90M, a 589.47% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $5.29M.
- INOVIO PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$18.09M.
- INOVIO PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$21.54M, a 141.82% decline from fiscal 2024.
- INOVIO PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $51.50M.
- INOVIO PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$32.02M.
- INOVIO PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$24.81M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.75M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | -$18.00M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | -$21.54M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | -$29.25M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | -$41.46M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$25.90M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $51.50M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $7.38M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $20.08M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $5.29M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$32.02M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | -$27.52M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $6.38M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$18.09M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | -$24.81M 10-K · filed 2024-03-06 | |||
| 2022-09-30 | -$49.16M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$30.04M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$12.13M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | -$179.58M 10-K · filed 2024-03-06 | |||
| 2021-09-30 | -$182.79M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$191.80M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$167.09M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $228.53M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $156.50M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $193.24M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $136.25M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$1.50M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | -$7.84M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | -$3.96M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | -$2.91M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$92.95K 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$4.39M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | -$8.70M 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $13.72M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $4.65M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |